cefaclor (ceclor) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.   NCATS

Chemistry

  • SMILES: N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1
  • InChIKey: QYIYFLOTGYLRGG-GPCCPHFNSA-N
  • Mol. Mass: 367.81
  • ALogP: 0.62
  • ChEMBL Molecules:
    cefaclor  
    cefaclor  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.3031 - $8.9625

United States

$0.7236 - $1.6975
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid | alfacet | bacticlor mr | ccl | ceclor | ceclor cd | cefaclor | cefaclor anhydrous | cefaclor hydrate | cefacloro | cefaclorum | céfeaclor | cephaclor | compound 99638 | distaclor | distaclor mr | keftid | losefar | raniclor

Organizations (13)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (10)


 

Bronchitis, Chronic

Infections

Otitis Media

Pharyngitis

Pneumonia

Respiratory Tract Infections (approved 2002)

Sprains and Strains

Staphylococcal Skin Infections (approved 2002)

Tonsillitis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Endocarditis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue